- Report
- April 2024
- 30 Pages
Global
From €2614EUR$2,750USD£2,196GBP
- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 143 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 134 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- August 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- April 2024
- 30 Pages
Global
From €2614EUR$2,750USD£2,196GBP
- Report
- November 2023
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- February 2023
- 175 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- August 2022
- 120 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2023
- 120 Pages
Global
From €7130EUR$7,500USD£5,990GBP
- Report
- December 2022
- 106 Pages
North America
From €1426EUR$1,500USD£1,198GBP
- Report
- February 2024
- 92 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP

The Loperamide market is a segment of the Over the Counter (OTC) Drugs industry. It is composed of products containing the active ingredient loperamide, which is used to treat diarrhea. These products are available in various forms, such as tablets, capsules, and liquids. They are typically sold in pharmacies, supermarkets, and other retail outlets.
Loperamide is a safe and effective treatment for diarrhea, and is often used as a first-line treatment for mild to moderate cases. It is also used to treat symptoms of irritable bowel syndrome and traveler's diarrhea.
The OTC Drugs industry is highly competitive, and the Loperamide market is no exception. Companies in the market compete on price, product quality, and marketing.
Some companies in the Loperamide market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Bayer, and Novartis. Show Less Read more